The "HBV eAg- Disease-Directly Offers" Study: Treatment Withdrawal in Patients With Early-Antigen Negative Chronic HBV
a study on Hepatitis B
The investigators' research is aimed at developing more effective, finite approaches for managing individual patients with chronic hepatitis B (CHB). This prospective clinical and basic scientific study exclusively focuses on patients with the early antigen negative form of disease, which in developed countries is treated indefinitely with antiviral drugs. The investigators' study "BeNEG-DO," directly offers patients who are already taking standard oral Hepatitis B Virus (HBV) antiviral therapy for at least 192 weeks the option to stop or continue treatment. Drawing on data from pilot studies, including the investigators' own University of California, San Francisco and Sutter Institutional Review Board-approved study, the investigators will examine a finite HBV treatment strategy on clinical outcome and safety. In conjunction, the investigators will study immunologic mechanisms and gene expression profiles that correlate with and predict the post-treatment clinical course. The BeNEG-DO study could seriously question, and potentially change, the current treatment paradigm for millions of patients with CHB and also lead to new disease-terminating antiviral therapeutics.
"BeNEG-DO": A Study of Clinical Outcomes, Immunologic Correlates and Genetic Predictors After Treatment Withdrawal in Early-Antigen Negative (HBeAg-) Chronic Hepatitis B Virus (HBV) Infection
A prospective case-control study of safety and clinical outcomes, and of innate and adaptive immune responses and their genetic predictors, in adult human subjects with HBeAg-CHB who either continue or stop nucleoside or nucleotide analog (NA) antiviral therapy. Immune responses will be studied using liver tissue and serial peripheral blood samples. The immunological factors selected have been chosen based on preliminary and inferential evidence. Immunologic findings will be correlated with different serologic, virologic and biochemical outcomes. Genetic predictors of the type of response and respective clinical outcomes will also be sought.
Chronic Hepatitis BHepatitisHepatitis, ChronicHepatitis BHepatitis B, ChronicStop NA therapy
You can join if…
Open to people ages 18-67
- HBeAg-CHB with at least 192 weeks (3.7 years) of complete viral suppression (serum HBV DNA <50 IU/ml) on NA therapy
- No bridging fibrosis (≥ Metavir stage 3)
- Normal liver tests and platelet count
- Age 18-67
- Otherwise healthy with no serious co-morbidities
- Patients who are willing, prepared, and able to immediately resume antiviral treatment upon medical instruction and on satisfying study re-treatment criteria.
You CAN'T join if...
- HBeAg-CHB with virologic breakthrough while on NA therapy during the prior 192 weeks (3.7 years)
- Age <18 or >67 years
- Significant co-morbidities including co-infection and significant co-existing liver disease or anemia. Mild Non-Alcoholic Fatty Liver Disease (NAFLD) without Non-Alcoholic Steatohepatitis (NASH) or associated liver enzyme elevation will be allowed.
- Bridging hepatic fibrosis (≥ Metavir stage 3) at the time of potential study entry
- Control Group: Determination will be based on historical biopsy data, imaging studies, Platelet count (<150,000), Aspartate aminotransferase to Platelet Ratio Index (APRI) <1.5) and Red Cell Distribution Width-to-Platelet Ratio (RPR) (<0.16) scores, and clinical assessment
- Alanine Aminotransferase (ALT) above the quoted normal range
- Clinical, serologic, radiological or biochemical suspicion for cirrhosis
- Prior liver transplantation
- A documented history of extrahepatic manifestations of hepatitis B, including renal disease and/or vasculitis
- Cases: A family history of hepatocellular carcinoma due to hepatitis B virus in a first degree family member
- . On Prednisone or other immunosuppressive or immune-modulating therapy during the 6 months before study entry
- . Pregnancy
- . Patients who are not willing, prepared, and able to immediately resume antiviral treatment upon medical instruction and on satisfying re-treatment criteria
No one will be excluded on the basis of race, gender, religion, sexual orientation, or any cultural factor. An Institutional Review Board (IRB)-approved, translated consent will be used for patients that do not speak English
- University of California, San Francisco
accepting new patients
San FranciscoCalifornia94122United States
- California Pacific Medical Center
accepting new patients
San FranciscoCalifornia94115United States
Lead Scientist at UCSF
- accepting new patients
- Start Date
- Completion Date
- California Pacific Medical Center Research Institute
- Study Type
- Last Updated
Please contact me about this study
We will not share your information with anyone other than the team in charge of this study. Submitting your contact information does not obligate you to participate in research.
The study team should get back to you in a few business days.
You will also receive an email with next steps. Check your junk/spam folder if needed.
If you do not hear from the study team, please call 888-689-8273 and tell them you’re interested in study number NCT02845401.